期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

TCRP1在口腔鳞癌中介导顺铂耐药的体内实验研究 被引量：3

Effects of TCRP1 on mediating resistance to cisplatin in vivo in OSCC
下载PDF
导出
摘要 目的 TCRP1是新近从舌癌耐药细胞系Tca8113/PYM中克隆出来的一个新基因,前期体外实验研究表明TCRP1在口腔鳞癌细胞中能特异地介导对顺铂化疗耐受,本研究将进一步探讨TCRP1在体内实验中介导化疗耐受的作用。方法通过建立TCRP1过/沉默表达裸鼠移植瘤模型,观测TCRP1对化疗药物5-Fu、cDDP的作用敏感性的影响并初步探讨其机制。结果肿瘤生长曲线及肿瘤瘤重结果显示TCRP1能增强裸鼠移植瘤对顺铂的耐药性,而对5-Fu则没有影响。TUNEL检测发现TCRP1高表达的组织中凋亡细胞计数更少。结论 TCRP1是一个新的耐药相关基因,其作用机制与通过增强口腔鳞癌细胞凋亡抗性有关。 Aim TCRP1 is a novel gene which was cloned from a multi-drug resistant cell line Tca8113/PYM in previous research.The preliminary functional investigation in vitro indicated that TCRP1 was a new chemo-resistance related gene,which mediated specifically resistance to cisplatin in Oral Squamous Cell Carcinoma（OSCC） cells.This study aims to futher explore the effect of TCRP1 in OSCC in vivo.Methods The effect of TCRP1on sensitivity to cisplatin and 5-Fu was observed through establishing the ectopic tumor animal model of over/silence expression of TCRP1,and then the initiatory mechanism was imvestigated.Results The outcome of tumor growth curves and tumor weight displayed that TCRP1 significantly increased the resistance to cisplatin in OSCC ectopic tumor,but not to 5-Fu.And the TUNEL assay indicated there were fewer number of apoptosis cells in up-regulated TCRP1 tumor tissue.Conclusion TCRP1 is a novel chemo-resistance related gene,and its functional mechanism is correlated with reducing the cells apoptosis induced by cisplatin.
作者 谷依学 范莎莎 王成昆 彭波 张为家 贺智敏
机构地区 广州医学院附属肿瘤医院肿瘤研究所 中南大学湘雅医学院肿瘤研究所
出处 《中国药理学通报》 CAS CSCD 北大核心 2012年第11期1574-1578,共5页 Chinese Pharmacological Bulletin
基金 国家自然科学基金资助项目(No 30873088) 教育部博士点基金资助项目(No 200805330009)
关键词 肿瘤 口腔鳞癌 顺铂 耐药 TCRP1 体内实验 凋亡 tumor OSCC cisplatin resistance TCRP1 experiment in vivo apoptosis
分类号 R329.25 [医药卫生—人体解剖和组织胚胎学] R73-34 [医药卫生—肿瘤]
  • 相关文献

参考文献2

二级参考文献30

  • 1Mimeault M,Hauke R,Batra S K.Recent advances on the molecular mechanisms involved in the drug resistance of cancer cells and novel targeting therapies[J].Clin Pharmacol Ther,2008,83(5):673-91.
  • 2Igney F H,Krammer P H.Death and anti-death:tumour resistance to apoptosis[J].Nat Rev Cancer,2002,2(4):277-88.
  • 3Shabbits J A,Hu Y,Mayer L D.Tumor chemosensitization strategies based on apoptosis manipulations[J].Mol Cancer Ther,2003,2(8):805-13.
  • 4Green D R,Kroemer G.Pharmacological manipulation of cell death:clinical applications in sight?[J].J Clin Invest,2005,115(10):2610-7.
  • 5Galluzzi L,Larochette N,Zamzami N,Kroemer G.Mitochondria as therapeutic targets for cancer chemotherapy[J].Oncogene,2006,25(34):4812-30.
  • 6Kang M H,Reynolds C P.Bcl-2 inhibitors:targeting mitochondrial apoptotic pathways in cancer therapy[J].Clin Cancer Res,2009,15(4):1126-32.
  • 7Trauzold A,Schmiedel S,Oestern S,et al.Concerted deregulations of multiple apoptosis-controlling genes in pancreatic carcinoma cells[J].Ann N Y Acad Sci,2003,1010:510-3.
  • 8Lu C,El-Deiry W S.Targeting p53 for enhanced radio-and chemo-sensitivity[J].Apoptosis,2009,14(4):597-606.
  • 9Eischen C M,Lozano G.p53 and MDM2:antagonists or partners in crime[J]?Cancer Cell,2009,15(3):161-2.
  • 10Mazars A,Geneste O,Hickman J.The Bcl-2 family of proteins as drug targets[J].J Soc Biol,2005,199(3):253-65.

共引文献13

同被引文献24

  • 1Deshmukh RR,Schmitt SM,Hwang C,et al.Chemotherapeutic inhibitors in the treatment of prostate cancer[J].Expert Opin Pharmaeother,2014,15 ( 1 ) : 11-22.
  • 2Peng B, Gu Y, Xiong Y, et al.Microarray-assisted pathway analysis identifies MT1X & NF K B as mediators of TCRPl-associated resistance to cisplatin in oral squamous cell carcinoma[J].PLoS One, 2012, 7 (12) : e51413.
  • 3Easwaran H, Tsai HC, Baylin SB.Cancer epigenetics:tumor heterogeneity,plasticity of stem-like states,and drug resistance[J]. Mol Cell, 2014, 54 (5) : 716-727.
  • 4Gu Y, Fan S, Xiong Y, et al.Cloning and functional characterization of TCRPI,a novel gene mediating resistance to cisplatin in an oral squamous cell carcinoma cell line[J].FEBS Lett, 2011, 585 ( 6 ) : 881-887.
  • 5Massano J, Regateiro FS, Januario G, et al. Oral squa- mous cell carcinoma: review of prognostic and predictive factors I J]. Oral Sttrg Oral Med Oral Pathol Oral Radiol Endod, 2006, 102(1): 67-76.
  • 6Magrath I, Litvak J. Cancer in developing countries: op- portunity and challengeE J. J Natl Cancer Inst, 1993, 85 ( 11 ) : 862-874.
  • 7Simons AL, Mattson DM, Dornfeld K, et al. Glucose deprivation induced metabolic oxidative stress and cancer therapyEJl. J Cancer Res Ther, 2009, 5 Suppl 1: s2-6.
  • 8Zhu H, Liu Z, Tang L, et al. Reversal of P-gp and MR- PI-mediated multidrug resistance by H6, a gypenoside ag- lycon from gynostemma pentaphyllum, in vincristine-re- sistant human oral cancer (KB/VCR) cells [ J ]. Eur J Phanacol, 2012, 696(1-3): 43-53.
  • 9Arriagada R, Bergman B, Dunant A, et al. Cisplatin- based adjuvant chemotherapy in patients with completely resected non-small-cell lung cancer J ]. N Engl J Med, 2004, 350(4): 351-360.
  • 10Cooper JS, Pajak TF, Forastiere AA, et al. Postoperative concurrent radiotherapy and chemotherapy for high risk squamous cell carcinoma of the head and neck [ J ]. N Engl J Med, 2004, 350(19) : 1937-1944.

引证文献3

二级引证文献1

中国药理学通报
2012年 第11期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部